Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Second Affiliated Hospital, Zhejiang University, School of Medicine: Clinical Trials & FDA Approval Profile

Second Affiliated Hospital, Zhejiang University, School of Medicine (Global / Institutional) sponsors 195 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 122 active protocols (81 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.5%
Median Closed Enrollment vs National (145 pts)58 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Second Affiliated Hospital, Zhejiang University, School of Medicine
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)195
Active Pipeline (Recruiting Now)122 (81)
Completed vs Stopped Early8 / 3 (1.5%)
Median Closed Actual Enrollment58 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Second Affiliated Hospital, Zhejiang University, School of Medicine
Hospital Research SiteLocationShared Protocols
The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou20
The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang17

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07575672Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailurePhase IIIRECRUITING
NCT06375005Efficacy and Safety of Telitacicept in the Treatment of Systemic SclerosisPhase IIRECRUITING
NCT07022223Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaPhase IIRECRUITING
NCT0487961524 Hours Treatment with Alteplase in Patients with Ischemic StrokePhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Second Affiliated Hospital, Zhejiang University, School of Medicine Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI